Experts veto Avastin as a breast cancer treatment A panel of cancer experts said Tuesday that the government should remove its endorsement of Roche’s drug Avastin for breast cancer, after follow-up studies failed to show benefits for patients. Read more on Channel 8 San Diego Share and Enjoy:
Pull Avastin for breast cancer, U.S. panel says U.S. federal health advisers said overwhelmingly that the Roche drug Avastin’s approval for breast cancer should be withdrawn after followup studies failed to show meaningful benefits for patients. Read more on CBC.ca Share and Enjoy:
Roche Avastin Trials Not as Good as Early Tests Roche Holding AG’s top-seller Avastin didn’t slow breast tumors in new studies as much as in earlier tests used to win approval, according to U.S. regulators weighing whether to permit sales to continue for this purpose. Read more on BusinessWeek Share and Enjoy:
After cuts, Roche says it’s growing By most outward appearances, Roche Diagnostics seems to be going through a rough patch. Behind the scenes, however, the maker of medical tests and devices says it is pushing forward aggressively with new products. It’s also hiring workers and investing millions of dollars in laboratories, factory expansion, call-center consolidation [...]
Roche Aims to Expand Rituxan Label Roche and Biogen Idec have submitted a supplemental Biologics License Application to the FDA for the label expansion of Rituxan . Read more on Zacks.com via Yahoo! Finance Share and Enjoy:
The Next Magic Bullets For Cancer? A trove of new cancer drugs could come in the next few years, says a top Roche researcher. Read more on Forbes Share and Enjoy: